The Weekly Roundup: November 7-11

POLL: Have You Ever Treated Blastic Plasmacytoid Dendritic Cell Neoplasm?

Click here to answer this week's poll.

An Overview of Argyria

Argyria is a rare dermatologic condition that presents with blue or grey mucocutaneous discoloration following cutaneous exposure or ingestion of silver.

Approaching Plaque Psoriasis Treatment Based on Comorbidities

Expert dermatologists discuss how to select treatment for plaque psoriasis while taking comorbidities into consideration.

Role of IL-17 Inhibitor Durability in Plaque Psoriasis

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss the durability of IL-17 inhibitors in managing plaque psoriasis.

The Mainstream Patient: November 7

This week's edition of the Mainstream Patient features stories about how to take care of the skin's microbiome, Clinique's commitment to the Latinx community, laser treatment results for rosacea, and more.

Case 1: 28-Year-Old Female Patient With Psoriasis

Mark G. Lebwohl, MD, introduces the case of a 28-year-old female nurse with a long history of psoriasis, commenting on her past medical history and initial presentation.

The Benefits of Topical Ruxolitinib

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, examine the clinical context for the approval of topical ruxolitinib and its role in the treatment armamentarium.

Oral Agents for the Treatment of Atopic Dermatitis

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, talk about the use of oral systemic agents and what they’ve learned about the patient experience from the use of these agents.

Case 1: Treatment and Disease Management Challenges

Dr Mark Lebwohl comments on the treatment and management considerations for a patient suffering from severe generalized pustular psoriasis, highlighting the inefficiency of systemic steroids in the management of this condition.

Case 1: Treatment and Disease Management Goals

Goals of generalized pustular psoriasis treatment are reviewed by Dr Mark Lebwohl, where he comments on the need to consider patient disease severity and comorbidities.

FDA Accepts Phase 1 Clinical Trials of Exosome Therapy for AD

Brexogen Inc.’s exosome therapy is the first entry of a clinical trial of exosome treatment for atopic dermatitis.

David Light, CEO of Valisure, Reviews Petition Sent to FDA Regarding Benzene Contamination

Valisure, an independent laboratory, recently sent a Citizen's Petition to the FDA regarding high levels of benzene found in dry shampoo products.

Muneeb Shah, DO, Discusses What it Means to Have Healthy Skin

November kicks off National Healthy Skin Month, presenting an opportunity to learn new habits for healthier skin.

Personalized Solutions Boost Medication Adherence

For the past 20 to 25 years, data has shown that half of patients prescribed long-term medications do not take them as prescribed.

Eli Lilly Submits BLA for Lebrikizumab AD Treatment

BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.

Pointers with Portela: RoC Fill + Treat Review

In this week’s Pointers with Dr Portela, the 208SkinDoc reviews RoC's Fill + Treat Serum.

Dermatologist Faces Lawsuit for Terminating an Employee

In this month's Legal Eagle column, David J. Goldberg, MD, JD, reviews a lawsuit case regarding employee termination.

How to Have a Proper Presence on Social Media

Tips on growing your practice.

Best Practices for Recruiting Talented Staff for Your Practice

Medical practices must go beyond simply offering competitive salaries and benefits packages to attract new talent and keep their best clinicians and administrative staff working for them.

Positive New Results of Tapinarof Cream Study for Pediatric Patients with AD

Dermavant announced positive results from its pediatric maximal usage study.

Hidradenitis Suppurativa: Current and Future Treatments

Hidradenitis suppurativa is a chronic inflammatory skin condition that presents with painful, deep, and inflamed lesions found in flexural, apocrine gland-bearing sites.